The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

USC is leading a research team aiming to better understand retinitis pigmentosa and inform future treatments.

HALT, pairs Amarna’s SV40-derived gene delivery vector platform with Phenocell’s in vitro AMD disease model, which accurately ...

Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of ...

Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation ...

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...

VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of ...

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a ...

SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug ...

A University of Colorado study links air pollution to increased ocular health issues, finding patient visits for irritation ...